Skip to Content

Reata Pharmaceuticals, Inc.

Merger

  • Date:
  • 7/28/2023
  • Company Name:
  • Reata Pharmaceuticals, Inc.
  • Stock Symbol:
  • RETA
  • Company Name - Buyer:
  • Biogen Inc.
  • Stock Symbol - Buyer:
  • BIIB
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 7/28/2023

Case Finder

Locate any case using the tools below.

NEW YORK, August 1, 2023 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) (“Reata”) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Biogen Inc. (NASDAQ: BIIB) (“Biogen”).

On July 28, 2023, Reata announced that it had entered into an agreement to be acquired by Biogen in a $7.3 billion all-cash deal. Pursuant to the merger agreement, Biogen has agreed to acquire Reata for $172.50 per share in cash. The deal is expected to close in the fourth quarter of 2023.

Bragar Eagel & Squire is concerned that Reata's board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Reata's stockholders.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Reata Pharmaceuticals. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: